CHINA PHARMA HOLDINGS, INC.

Regulatory Filings • Dec 26, 2024

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 23, 2024

CHINA PHARMA HOLDINGS, INC.

(Exact name of Registrant as specified in charter)

Nevada	001-34471	73-1564807
(State or other jurisdiction	(Commission File No.)	(IRS Employer
of Incorporation)		Identification No.)

Second Floor , No. 17, Jinpan Road

Haikou , Hainan Province , China 570216

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: + 86 898-6681-1730 (China)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

☐ Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CPHI	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 1.02. Termination of a Material Definitive Agreement.

On December 23, 2024, China Pharma Holdings, Inc., (the “Company”) and that certain investor (the “Investor”) reached an agreement to rescind (the “Recission”) that certain securities purchase agreement (the “Agreement”) dated December 12, 2024. The material terms of such Agreement were disclosed in the current report on Form 8-K filed by the Company with the Securities and Exchange Commission on December 13, 2024. As a result of such Recission, the Agreement is deemed void from the beginning.

Field: Page; Sequence: 2; Options: NewSection; Value: 1

Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 26, 2024

/s/ Zhilin Li
Name:	Zhilin Li
Title:	President and Chief Executive Officer

2

Field: Rule-Page

Field: /Rule-Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjU0KwkAMhU/QO4RZiz+DddGdFhWxihQRt4NNZbCdlMyo9Uje0tgihkAS3vtelBqoNa1shQznRZ7BEeumMgEhxxIZ3QXFkW62CcjM8Wp9YONCd/7AlIRBYeKhjo0InfVhPRYJTPRIz0Z6Kksy0TDfqeirp+RKW6AL1lRgXAEHpoYtBsOvPuFoWnJUv7pXJ2RvyUnccNzLb9BjydvTwzyJbx6yLFXRoKtIrZnujbiWbUD3JWFZYS3vfE//O/oA/flKfQ==